Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker HLN · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Oct 2, 2026 | EXCEDRIN MIGRAINE GELTABS, EXCEDRIN MIGRAINE, TRAVEL BASIX,… ACETAMINOPHEN; ASPIRIN; CAFFEINE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA020802 ↗ |
| Jun 26, 2026 | CHILDRENS ADVIL IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA020589 ↗ |
| May 1, 2026 | JUNIOR STRENGTH ADVIL IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA020944 ↗ |
| May 1, 2026 | CHILDRENS ADVIL IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA020589 ↗ |
| Apr 14, 2026 | ABREVA DOCOSANOL | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA020941 ↗ |
| Mar 27, 2026 | ALLI ORLISTAT | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA021887 ↗ |
| Dec 19, 2025 | CHILDRENS FLONASE ALLERGY RELIEF, FLONASE ALLERGY RELIEF FLUTICASONE PROPIONATE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA205434 ↗ |
| Dec 19, 2025 | FLONASE SENSIMIST ALLERGY RELIEF FLUTICASONE FUROATE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022051 ↗ |
| Sep 15, 2025 | FLONASE SENSIMIST ALLERGY RELIEF FLUTICASONE FUROATE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022051 ↗ |
| May 5, 2025 | ADVIL DUAL ACTION WITH ACETAMINOPHEN, ADVIL DUAL ACTION WIT… ACETAMINOPHEN; IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA211733 ↗ |
| Mar 17, 2025 | NICORETTE, NICORETTE PEPPERMINT, NICORETTE CHERRY PEPPERMINT NICOTINE POLACRILEX | HLN Haleon US Holdings | New drug (NDA), supplement Manufacturing (CMC) | NDA022360 ↗ |
| Jan 10, 2025 | CHILDRENS FLONASE ALLERGY RELIEF, FLONASE ALLERGY RELIEF FLUTICASONE PROPIONATE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA205434 ↗ |
| Jan 10, 2025 | FLONASE SENSIMIST ALLERGY RELIEF FLUTICASONE FUROATE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022051 ↗ |
| Jan 8, 2025 | ADVIL LIQUI-GELS, ADVIL MIGRAINE, ADVIL IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA020402 ↗ Letter or label ↗ |
| Dec 30, 2024 | ADVIL IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA018989 ↗ |
| Nov 21, 2024 | NICORETTE, NICORETTE PEPPERMINT, NICORETTE CHERRY PEPPERMINT NICOTINE POLACRILEX | HLN Haleon US Holdings | New drug (NDA), supplement Manufacturing (CMC) | NDA022360 ↗ |
| Oct 24, 2024 | CHILDRENS FLONASE ALLERGY RELIEF, FLONASE ALLERGY RELIEF FLUTICASONE PROPIONATE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA205434 ↗ Letter or label ↗ |
| Oct 24, 2024 | FLONASE SENSIMIST ALLERGY RELIEF FLUTICASONE FUROATE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022051 ↗ Letter or label ↗ |
| Sep 9, 2024 | ADVIL PM DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Manufacturing (CMC) | NDA021393 ↗ |
| Sep 6, 2024 | NICORETTE NICOTINE POLACRILEX | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA021330 ↗ |
| Aug 7, 2024 | VOLTAREN ARTHRITIS PAIN DICLOFENAC SODIUM | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022122 ↗ |
| Apr 30, 2024 | NICORETTE, NICORETTE PEPPERMINT, NICORETTE CHERRY PEPPERMINT NICOTINE POLACRILEX | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022360 ↗ |
| Jan 3, 2024 | NICORETTE 4MG FRUIT CHILL GUM, LIL DRUG STORE, NICORETTE OR… NICOTINE POLACRILEX | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA020066 ↗ |
| Jan 3, 2024 | NICORETTE ORIGINAL, NICORETTE MINT, NICORETTE CINNAMON SURG… NICOTINE POLACRILEX | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA018612 ↗ |
| Nov 29, 2023 | VOLTAREN ARTHRITIS PAIN DICLOFENAC SODIUM | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022122 ↗ |
| Nov 15, 2023 | CHILDRENS FLONASE ALLERGY RELIEF, FLONASE ALLERGY RELIEF FLUTICASONE PROPIONATE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA205434 ↗ |
| Nov 15, 2023 | FLONASE SENSIMIST ALLERGY RELIEF FLUTICASONE FUROATE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022051 ↗ Letter or label ↗ |
| May 15, 2023 | EXCEDRIN MIGRAINE GELTABS, EXCEDRIN MIGRAINE, TRAVEL BASIX,… ACETAMINOPHEN; ASPIRIN; CAFFEINE | HLN Haleon US Holdings | New drug (NDA), supplement Manufacturing (CMC) | NDA020802 ↗ |
| Apr 17, 2023 | EXCEDRIN MIGRAINE GELTABS, EXCEDRIN MIGRAINE, TRAVEL BASIX,… ACETAMINOPHEN; ASPIRIN; CAFFEINE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA020802 ↗ |
| Feb 23, 2023 | ADVIL LIQUI-GELS, ADVIL MIGRAINE, ADVIL IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA020402 ↗ |
| Feb 21, 2023 | VOLTAREN ARTHRITIS PAIN DICLOFENAC SODIUM | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022122 ↗ |
| Feb 21, 2023 | ADVIL PM- DIPHENHYDRAMINE CITRATE AND IBUPROFEN TABLET, COA… DIPHENHYDRAMINE CITRATE; IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA021394 ↗ |
| Nov 23, 2022 | VOLTAREN ARTHRITIS PAIN DICLOFENAC SODIUM | HLN Haleon US Holdings | New drug (NDA), supplement Manufacturing (CMC) | NDA022122 ↗ |
| Sep 20, 2022 | CHILDRENS ADVIL IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Manufacturing (CMC) | NDA020589 ↗ |
| Feb 8, 2022 | ADVIL, ADVIL MENSTRUAL PAIN IBUPROFEN SODIUM | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA201803 ↗ |
| Jan 25, 2022 | ADVIL DUAL ACTION WITH ACETAMINOPHEN, ADVIL DUAL ACTION WIT… ACETAMINOPHEN; IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA211733 ↗ |
| Jan 25, 2022 | ADVIL LIQUI-GELS, ADVIL MIGRAINE, ADVIL IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA020402 ↗ Letter or label ↗ |
| Jan 11, 2022 | ADVIL PM DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA021393 ↗ |
| Jan 10, 2022 | ADVIL DUAL ACTION WITH ACETAMINOPHEN, ADVIL DUAL ACTION WIT… ACETAMINOPHEN; IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA211733 ↗ |
| Jan 10, 2022 | ADVIL PM- DIPHENHYDRAMINE CITRATE AND IBUPROFEN TABLET, COA… DIPHENHYDRAMINE CITRATE; IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA021394 ↗ |
| Dec 14, 2021 | ADVIL IBUPROFEN | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA018989 ↗ Letter or label ↗ |
| Dec 7, 2021 | EXCEDRIN MIGRAINE GELTABS, EXCEDRIN MIGRAINE, TRAVEL BASIX,… ACETAMINOPHEN; ASPIRIN; CAFFEINE | HLN Haleon US Holdings | New drug (NDA), supplement Manufacturing (CMC) | NDA020802 ↗ |
| Nov 23, 2021 | ADVIL ALLERGY AND CONGESTION RELIEF, ADVIL MULTI-SYMPTOM CO… CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHL… | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022113 ↗ |
| Nov 23, 2021 | ADVIL ALLERGY SINUS CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROC… | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA021441 ↗ |
| Nov 19, 2021 | ADVIL SINUS CONGESTION AND PAIN IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022565 ↗ |
| Nov 19, 2021 | ADVIL COLD AND SINUS IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA021374 ↗ |
| Nov 19, 2021 | ADVIL COLD AND SINUS IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA019771 ↗ |
| Nov 9, 2021 | NICORETTE NICOTINE POLACRILEX | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA021330 ↗ |
| Nov 3, 2021 | VOLTAREN ARTHRITIS PAIN DICLOFENAC SODIUM | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA022122 ↗ |
| Nov 3, 2021 | EXCEDRIN MIGRAINE GELTABS, EXCEDRIN MIGRAINE, TRAVEL BASIX,… ACETAMINOPHEN; ASPIRIN; CAFFEINE | HLN Haleon US Holdings | New drug (NDA), supplement Labeling | NDA020802 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 7:18 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates